Alexander Bastian speaks about the need for a sustainable model of pricing as related to cancer treatments and drug development. He talks about indication-based pricing or tumor-based pricing—says that is compelling, but not necessarily possible in the US.
Grant Lawless discusses the changing landscape of pricing personalized medicines
Jayson Slotnik discusses the cost structure of diagnostics and pharmaceuticals in personalized medicine
Randy Vogenberg discusses the complexities of developing pricing for personalized medicine products
Matthew Palmgren discusses the benefits of personalized medicines